Abicipar Pegol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Abicipar Pegol
Accession Number
DB12258
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Abicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
M55Q728KNA
CAS number
1327278-94-3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Antihemophilic Factor (Recombinant), PEGylatedThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Antihemophilic Factor (Recombinant), PEGylated.
Cepeginterferon alfa-2BThe therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Abicipar Pegol.
Certolizumab pegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Certolizumab pegol.
Damoctocog alfa pegolThe therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Abicipar Pegol.
Egaptivon pegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Egaptivon pegol.
ElapegademaseThe therapeutic efficacy of Elapegademase can be decreased when used in combination with Abicipar Pegol.
Eptacog alfa pegol (activated)The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Eptacog alfa pegol (activated).
GlycoPEG-GCSFThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with GlycoPEG-GCSF.
Heptaethylene glycolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Heptaethylene Glycol, Peg330.
Insulin peglisproThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Insulin peglispro.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911306

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMacular Degeneration2
2CompletedTreatmentMacular Degeneration3
2CompletedTreatmentMacular Edema (ME)1
3Active Not RecruitingTreatmentMacular Degeneration2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:44 / Updated on June 04, 2019 07:35